---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005822"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:24:48.456117+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY

## Summary
- Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.
- Net loss narrowed to $443.3M from $704.5M in 2021; cash position $1.0B as of Dec 31, 2022.
- Expects commercial profitability in 2023 and overall corporate profitability by end of 2025.
- Key pipeline milestones: BLA submission for efgartigimod in gMG, NDA for repotrectinib, and initiation of KarXT bridging study in China.
- Appointed Michel Vounatsos to Board and Rafael Amado as President, Global Oncology R&D.

## SEC filing metadata
- accession: 0001628280-23-005822
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/0001628280-23-005822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/zlab-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005822
- JSON: https://secwatch.observer/filing/0001628280-23-005822.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005822.txt

## Key facts
- Earnings Releases
  Zai Lab Ltd reported the year ended December 31, 2022 results: revenue $215.0 million.
  - Period: the year ended December 31, 2022
  - Revenue: $215.0 million
  - Result: reported results
  source text: ai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates – Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth – Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 – Company to host conference call and webcast on March 2, 2023, at 8:00 a.m.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/0001628280-23-005822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.